Re Agreements

Advanced Medical Solutions Grp PLC 21 August 2003 For Immediate Release 21 August 2003 Advanced Medical Solutions Group plc ('AMS' or the 'Company') announces two new supply agreements for its advanced woundcare products Winsford, UK: AMS, the global woundcare technology company today announced that it has entered into two new supply and distribution agreements with B. Braun Hospicare and TEVA Medical Ltd allowing for major international business expansion. The first agreement with B. Braun Hospicare is for the supply of alginate products into the Professional Woundcare market under B. Braun's Askina Sorb brand. Alginate is a natural polymer derived from seaweed, which promotes wound healing by absorbing excess fluid, controlling bleeding and forming a gel, which keeps the surface of the tissue moist thus reducing scarring. B. Braun Hospicare is part of the OPM division (Out Patient Market) of B. Braun, the €2.6 billion turnover international healthcare company. Based in Sligo, Ireland, B. Braun Hospicare is part of the global centre of excellence for chronic woundcare development and manufacturing for the group, which markets its products extensively in Europe and the US. Under the terms of the agreement announced today, AMS will supply alginate roll-stock for converting and packaging by B. Braun Hospicare and a range of finished, packed product. Commenting on this agreement, Dr Don Evans, Chief Executive Officer of AMS, said: 'We are delighted to have added B. Braun Hospicare as a global partner to exploit our alginate technology further. With the strength of the Askina Sorb brand and its broad market presence, this agreement with B. Braun Hospicare offers an excellent opportunity to expand our business in major international markets'. Dr. Lawrence Storey, Managing Director of B. Braun Hospicare added: 'AMS is an ideal technology partner for our woundcare business offering a wide range of materials and products from a state of the art medical device facility. We look forward to developing our relationship and adding further products from the impressive AMS new product pipeline to our range.' ***************** In a separate statement released today; AMS have also signed an agreement with TEVA Medical Ltd for the supply and distribution of a range of advanced woundcare products in Israel. TEVA Medical Ltd, is part of TEVA Pharmaceutical Industrial Ltd. one of the largest generic pharmaceutical companies in the world with sales of over €2 billion. Commenting on this agreement, Don Evans said: 'The addition of TEVA Medical Ltd to our list of partners further strengthens the global distribution of our woundcare products by giving us entry into a new market and establishes a relationship with another major distributor.' - ENDS - For further information, please contact: Advanced Medical Solutions Group plc Tel : +44 (0) 1606 863 500 Don Evans, Chief Executive Officer Mary Tavener, Finance Director www.admedsol.com Buchanan Communications Tel: +44 (0) 20 7466 5000 Tim Anderson, Mary-Jane Johnson Notes to Editors: Advanced Medical Solutions is a leading company in the development and manufacture of products for the £15 billion global woundcare market. Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative and technologically advanced products for woundcare and other medical applications. In-house natural and synthetic polymer technology is used to provide advanced wound dressings based on the moist healing principle. AMS's resources ensure a unique position as a vertically integrated 'one stop shop' to provide all categories of moist wound healing products. The Company has the capability to move from product design and development through to production and delivery ready for distribution into customer markets. The acquisition of MedLogic in 2002 has brought AMS products and technology in cyanoacrylate based tissue adhesives and sealants sold direct to A & E departments or through distributors. AMS's technology and products currently serve the majority of the key global markets with strategic partners including 3M, Novartis, Johnson & Johnson, Molnlycke Healthcare, Coloplast, Smith + Nephew and Beiersdorf. This information is provided by RNS The company news service from the London Stock Exchange
UK 100